Last reviewed · How we verify
T-20
At a glance
| Generic name | T-20 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?
- The ESTxENDS Trial- Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation-extension of Follow-up (NA)
- Platelet-rich Plasma in Symptomatic Knee Osteoarthritis (NA)
- Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules (NA)
- Adding New Drugs for HIV Infected Patients Failing Current Therapy (PHASE1,PHASE2)
- Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children (PHASE1)
- Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults (NA)
- A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- T-20 CI brief — competitive landscape report
- T-20 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI